We report here the long term follow-up on 162 patients with high risk CLL who have undergone hematopoietic stem cell transplantation (SCT) at a single center from 1989 to 1999. Twenty-five patients with HLA matched sibling donors underwent T cell depleted allogeneic SCT and 137 patients without HLA matched sibling donors underwent autologous SCT. The 100-day mortality was 4% for both groups, but later morbidity and mortality negatively impacted on outcome. Progression-free survival was significantly longer following autologous than allogeneic SCT, but there was no difference in overall survival and no difference in the cumulative incidence of disease recurrence or deaths without recurrence between the two groups. At a median follow-up of 6.5 years there is no evidence of a plateau of progression-free survival. The majority of patients treated with donor lymphocyte infusions after relapse responded, demonstrating a significant graft versus leukemia effect in CLL. Based upon these findings we have altered our approach for high-risk patients with CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced intensity conditioning regimens.
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the presence in the peripheral blood of a clonal population of small B-lymphocytes expressing the characteristic morphology and immunophenotype with cells expressing CD19, CD5 and CD23.
Although Fludarabine has emerged as the treatment of choice in this disease, there is no evidence to date that conventional therapy is curative. 1 Despite the high initial response rates reported with conventional chemotherapy, patients invariably relapse and subsequently develop resistance to chemotherapy.
Stem cell transplantation (SCT) has become the treatment of choice for an increasing number of selected patients with hematological malignancies. However, relatively fewer patients with CLL have been treated with this approach. CLL is largely a disease of the elderly with a median age at presentation of more than 65 years, the majority of whom would not tolerate the toxicity associated with high dose myeloablative treatment approaches. The disease has a very long natural history so that there is reluctance to subject patients to a treatment approach with a significant morbidity and potential mortality and by the time of referral to transplant centers many of these patients have been very heavily pre-treated with development of chemo-resistant disease and decreased stem cell reserve. The majority of patients do not have a suitable allogeneic donor and the use of autologous bone marrow (BM) or peripheral blood stem cells (PBSC) has been hampered by the extensive leukemic infiltration of the bone marrow and peripheral blood involvement that is invariable with this disease.
There are nonetheless, reasons why investigators have examined the role of myeloablative treatment regimens in the management of CLL. [2] [3] [4] [5] [6] [7] [8] Up to 40% of patients
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From with CLL are under age 60 and 12% are under age 50 years at presentation and these younger patients almost invariably die of their disease or its complications. 9 The disease is characterized by chemo-sensitivity at least earlier in the disease course, providing a rationale for attempting to overcome subsequent drug resistance by the use of chemotherapy dose escalation. Although many patients with this often indolent disease are clearly not suitable candidates for approaches such as SCT, it is possible to identify patients with CLL who have sufficiently poor prognosis to merit more experimental treatment approaches with curative intent.
A clinical trial was initiated at Dana-Farber Cancer Institute (DFCI) in 1989 to establish the feasibility of performing high dose therapy with hematopoietic stem cell transplant (SCT) in CLL and the early results of the pilot study in previously relapsed patients was reported previously. 2 We now report the outcome and long term follow-up of 162 patients with high risk CLL who underwent autologous (n=137) or T cell depleted (TCD) allogeneic SCT from an HLA matched sibling donor (n=25). The 100-day mortality was 4% in both autologous and allogeneic SCT groups, although later treatment related mortalities had a major impact on outcome. With a median follow-up of 6.5 years there was no difference in overall survival and the six-year overall survival was 58% after autologous and 55% after allogeneic SCT. Progression-free survival was significantly longer following autologous than TCD allogeneic SCT, but no significant differences were observed in disease recurrence or deaths without recurrence according to type of transplant.
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Materials and Methods

Patients
From 1989 to 1994, eligible patients were patients with poor prognosis CLL who had relapsed after prior therapy (protocol 89-064). From 1994, patients with poor prognosis disease were also eligible for this approach in first complete or partial remission (protocol 94-055). The rationale for this change was that by 1994 many patients had received purine analog therapy before consideration for transplant and it was becoming increasingly difficult for such patients to achieve a protocol eligible minimal disease state in response to salvage therapy. The studies are combined for reporting here because 94-055 was a continuation of 89-064. There was no requirement for specific induction or salvage therapy prior to SCT on either protocol.
Patients with HLA-matched siblings underwent an allogeneic SCT, whereas all other patients underwent autologous SCT. The preparative regimen for both autologous and allogeneic patients was cyclophosphamide 60 mg/kg/day for two sequential days, followed by total body irradiation (TBI) administered at low dose rate of 10cGy per minute in seven fractionated doses of 200 cGy twice daily over four consecutive days to a total of 14 Gy total body irradiation. Within 18 hours of completion of radiotherapy, patients received either autologous BM that had been cryopreserved after purging with a cocktail of anti-B-cell monoclonal antibodies (anti-C20, anti-CD10 and B5) and complement 2, 10 or BM harvested from an HLA-identical sibling donor that had been treated in vitro with anti-CD6 monoclonal antibody and complement as previously described. 2, 11 Approval was obtained from the Dana-Farber Cancer Institute institutional 
Statistical Considerations
Progression-free survival (PFS) was defined as the length of time from the date of SCT to any recurrent or progressive disease or death, whichever occurred first. Overall survival (OS) was defined as the length of time from the date of SCT to death from any cause. PFS and OS percentages, standard errors, and treatment effect comparisons were obtained from the Kaplan-Meier method, 14 Greenwood's formula, 15 and log-rank test 16 respectively. Cumulative incidence of relapse is reported with death in remission as the competing risk. 17 Cumulative incidence of MDS for the patients who underwent
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From autologous transplant is reported with death as the competing risk. 17 Patients were evaluated in groups classified as having received an autologous transplant or an allogeneic transplant, but it should be stressed that any such comparison of autologous transplanted patients with allogeneic transplanted patients is not a randomized comparison. The Wilcoxon rank-sum test 18 was used for testing differences between continuous variables, and associations between categorical variables were assessed by a Fisher exact test. 19 All probability values were obtained from two-sided tests. The results are reported at a median follow-up of 6.5 years.
Results
Patient Characteristics
To be eligible for this approach, patients up to 66 years had to have poor prognosis CLL, factors including rapid doubling time (less than 12 months), 21, 22 diffuse bone marrow involvement 23 or adverse cytogenetics. 24, 25 This protocol had completed accrual before fluorescent in situ hybridization techniques became widely adopted to define prognosis in CLL. 26 Patients had to achieve a protocol eligible minimal disease state defined as no nodal masses greater than two centimeters and bone marrow infiltration less than 30% after therapy. Twenty seven patients with persistent splenomegaly greater than 15 cm on computerized tomography scanning who had otherwise achieved protocol eligibility underwent splenectomy before transplant. There were no specific requirements for previous therapy and patients were eligible for enrollment once they had achieved the One hundred and thirty-seven patients without an HLA matched sibling donor underwent B-cell purged autologous SCT and 25 patients with an HLA-matched sibling donor underwent T-cell depleted (TCD) allogeneic SCT. The median age for all patients was 49 (range19 to 66) years, 97% were Caucasian and 75% were male, in keeping with the male preponderance and the poorer prognosis status of male patients with CLL. 27 The median time from diagnosis to transplant was 46 months for autologous SCT and 45 months for allogeneic SCT. There were no requirements for prior therapy and 10 patients (6%) received only alkylator agents, 37 patients (20%) received only fludarabine therapy and all others received both alkylator and fludarabine therapy either sequentially (70 patients) or concomitantly (45 patients patients who underwent autologous SCT died without evidence of disease progression after 100 days, all but one of which (death in a road traffic accident) could potentially be related to the procedure so that the overall treatment related mortality in the patients undergoing autologous SCT could be as high as 17%. One patient (4%) who underwent allogeneic SCT died within 100 days of a rapidly progressive high-grade lymphoma. This lymphoma was negative for expression of Epstein-Barr virus and was not related to her underlying CLL comparison of the sequence of the IgH rearrangement of the CLL cells compared to her lymphoma cells. Five additional patients also died after day 100 in the patients undergoing allogeneic SCT, all procedure related, so that the overall treatment related mortality after T-cell depleted allogeneic SCT was 24%. The causes of death without evidence of disease progresion in all patients are shown in Table 2 .
Disease progression after stem cell transplant
The response criteria for complete remission in CLL include a return of hemoglobin to greater than 11 g/L and platelet count greater than 100 x 10 9 /L, but allow for up to 30% remaining lymphocytes in the BM. 30 These are not ideal criteria to apply to patients undergoing SCT in whom we are more interested in whether there are residual We observed that patients transplanted most recently had significantly worse PFS (P=0.01) than patients transplanted earlier (Figure 5a ), although there is at present no difference in overall survival (Figure 5b) (P=0.14) . Whether this reflects a difference in risk status of these later patients, or differences of the impact of prior therapy on outcome after transplant is not clear at present. A previous study suggested that patients with mutated IgH rearrangements have better outcome after autologous SCT than those with unmutated IgH. 33 Although in the present study more than 90% of the patients have unmutated IgH (Table 1 ), suggesting that we had indeed selected high risk CLL patients for this approach, we observed no difference in progression-free survival (p=0.18) or overall survival (p=0.47) for those patients who had mutated compared to those with unmutated IgH rearrangements ( Figure 6 ).
Second malignancies after stem cell transplant
Second (non CLL) malignancies have developed after SCT in 31 (19%) patients ( 
Discussion
We describe here the outcome of 162 patients with high risk CLL who have undergone autologous or allogeneic SCT at a single center. Long-term follow-up is important after experimental treatment approaches for patients with malignancies such as CLL that have such long natural history. These myeloablative regimens were associated with a
short-term treatment related mortality of 4%, but later relapse and non-relapse mortality negatively impacted outcome. Although there is no clear evidence of a plateau for survival or progression free survival in this study, 21 patients remain alive, 12 of whom remain disease free and in molecular complete remission more than 8 years after transplant (unpublished observation). We observed no evidence that patients transplanted in first remission had better outcome than those treated after previous relapse and that there was no improvement in outcome after autologous SCT using combined chemotherapy and monoclonal antibody than those treated with older regimens. It is difficult to assess the impact of transplantation on survival of the patients reported here, but the six year overall survival after transplantation of 58% appears better than would be expected in these high risk CLL patients, particularly when over 90% of these patients had unmutated IgH status. 33 It must be stressed however, that this analysis is not performed on intent to treat basis, and patients were enrolled at the time of achieving eligibility and referral to a transplant center. These findings in CLL appear similar to those observed in multiple myeloma. 34 In this disease setting, although autologous SCT does not appear curative, it is still associated with improved outcome compared to conventional therapy. 35 A number of studies have examined the feasibility and outcome of autologous and allogeneic SCT in CLL. 2, 3, [5] [6] [7] [8] Autologous SCT was feasible in 67% of young patients with CLL who were enrolled in a prospective multi-center study, 8 and a retrospective matched pair analysis suggested a survival advantage for autologous SCT over conventional therapy. 33 Although we observed no difference in outcome between autologous and allogeneic SCT in the present study, previous studies have suggested an improved outcome for patients with CLL undergoing allogeneic compared to autologous SCT, 3 particularly in patients with poor risk features such as unmutated IgH status, 36, 37 For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From suggesting a graft versus leukemia (GVL) effect in this disease that is responsible for the low likelihood of late relapses occurring after allogeneic transplantation for low grade B cell malignancies. We performed T cell depletion to attempt to decrease the morbidity and mortality of allogeneic SCT, and it is likely that this also resulted in loss of the beneficial impact on progression free survival of the GVL and that the increased late relapses seen here reflect the loss of GVL effect mediated by T cell depletion. The high subsequent response rate to DLI in CLL supports this conclusion. Only 15% of patients in the present study underwent allogeneic SCT. The reason for this relatively low number of patients with suitable donors likely reflects not only the difficulties of identifying suitable sibling donors in an older age group population, but also a referral bias of patients to our center at a time when other centers were offering allogeneic SCT, so that patients with an HLA matched donor could be referred to these other centers, whereas patients without donors would still be referred to our Institution. In keeping with the known familial incidence in CLL, 38 seven potentially suitable HLA matched donors were excluded when they were found to have evidence of B cell lymphoproliferative diseases.
Non-melanomatous skin cancers are common in older patients, but there is concern regarding the incidence of other secondary malignancies observed in this study. In particular, the risk of secondary MDS/AML has been observed as a consequence of autologous SCT after high dose therapy, particularly those including the use of TBI. [39] [40] [41] We had previously observed a high risk of MDS in patients with follicular non-Hodgkin's lymphoma (NHL) after TBI, 40 but at that time the incidence appeared low in the CLL patients. It was therefore possible that either the disease itself, or more likely the different frontline therapy delivered to these patients may have offered some protection against this complication. It now appears that the risk of secondary MDS is similar after TBI in both NHL and CLL and that long-term follow up was required to observe this complication. To date nine other cancers have occurred after autologous SCT. A higher risk of secondary cancers has been reported after CLL 42, 43 and these patients are also more elderly than many series of the use of autologous SCT in other malignancies, so it is presently not possible to state definitively the increased risk of the use of high dose therapy on these types of cancers. However, we caution that patients who have undergone high dose therapy require close long term monitoring to screen for the development of these malignancies.
We conclude that although the short-term complications of stem cell transplant after myeloablative conditioning regimens appears feasible and is associated with low toxicity, on long term follow up of these patients there is a high cost in terms of late treatment related complications including MDS and other cancers, and that disease progression did not appear to plateau in this high risk CLL population. Based upon these findings, the accumulating evidence of a powerful GVL effect in CLL 44 and the decreased mortality associated with reduced intensity conditioning regimen, 45 our current approach for highrisk CLL patients is to perform reduced intensity-conditioning allogeneic SCT from related and unrelated donors. Figure 5B
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